000			02760nam a22003495i 4500
999			_c399274 _d399274
001			399274
003			ES-MaUEC
005			20240518181834.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			230801s2023 sz | o |||| 0|eng d
020			_a9783031229039
024	7		_a10.1007/978-3-031-22903-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC269 _b2023 EB
245	0	0	_aCirculating Tumor Cells : _bAdvances in Liquid Biopsy Technologies _cedited by Richard J Cote, Evi Lianidou
250			_a2nd ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Cancer Research _x2199-2592
505	0		_aPart 1. CTC Technologies -- Affinity -- Physical -- ctDNA -- miRNA -- Exosomes -- Part 2 -- Biology of CTC -- Dormancy -- Culture -- EMT -- ctDNA and Exosomes -- Cells in circulation with CTC -- Part 3 -- CTC Analysis -- IHC, FISH, and other molecular assays -- Functional characterization -- Advanced microscopy and AI -- Analysis of non-cellular circulating markers -- Part 4 -- Clinical Applications of the Liquid Biopsy -- Early detection and cancer screening -- Prognosis and therapeutic monitoring -- Applications in Clinical Trials -- Applications in Drug Development.
520			_aIt is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clinical application. There has been an explosion of interest and progress in liquid biopsy technologies since the first edition of this book. The second edition will expand its focus to now include not only circulating tumor cells (CTC), but also other emerging aspects of the liquid biopsy, including circulating tumor DNA and methylated DNA (ctDNA, ct meDNA), ctRNA, ct miRNA, circulating tumor proteins (and other) biomarkers and circulating tumor derived exosomes (ctExosomes).
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9146156 _aCélulas cancerosas
650		7	_2embne _9139209 _aTumores _xBiopsia
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-22903-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b05/2024 _dz _eIG _zSI